Product Details

Product Description:

Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093 4067-01, b) 1000 Capsules, NDC 0093-4067-10

Reason for Recall:

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Product Quantity:

181,659 bottles

Recall Number:

D-0104-2026

Code Information:

a) NDC 0093-4067-01: Lot # 3010544A and 3010545A, Exp Date: 10/2025; Lot # 3010567A, Exp Date: 12/2025; Lot # 3010590A, Exp Date: 02/2026; Lot # 3010601A, 3010602A, 3010603A, Exp Date: 03/2026; Lot # 3010652A, 3010670A, 3010671A, Exp Date: 07/2026; Lot # 3010678A, 3010700A, 3010701A, Exp Dat 08/2026 b) NDC 0093-4067-10: Lot # 3010440A, Exp Date: 12/2025; Lot # 3010672A, Exp Date: 07/2026 **less...**

Classification:

Class II

Event Details

Event ID:

97755

Voluntary / Mandated:

Voluntary: Firm initiated

Product Type:

Drugs

Initial Firm Notification of Consignee or Public:

Letter

Status:

Ongoing

Distribution Pattern:

U.S. Nationwide

Recalling Firm:

Teva Pharmaceuticals USA, Inc
400 Interpace Pkwy Bldg A
Parsippany, NJ 07054-1120
United States

Press Release URL(s):

Press Release Not Issued For This Recall

Recall Initiation Date:

10/7/2025

Center Classification Date:

10/24/2025

Date Terminated:

N/A

***N/A -** *Not Available*

Update History

There is no history available for this product

Product Details

Product Description:

Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093 4068-01, b) 1000 Capsules, NDC 0093-4068-10

Reason for Recall:

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Product Quantity:

291,512 bottles

Recall Number:

D-0105-2026

Code Information:

a) NDC 0093-4068-01: Lot # 3010398A, 3010399A, 3010400A, 3010401A, 3010353A, Exp Date: 12/2025; Lot # 3010439A, 3010388A, Exp Date: 01/2026; Lot # 3010526A, 3010527A, Exp Date: 03/2026; Lot # 3010591A, 07/2026; Lot # 3010343A, Exp Date: 10/2025; Lot # 3010352A, Exp Date: 11/2025; Lot # 3010468A, 3010469A, 3010461A, Exp Date: 02/2026; Lot # 3010629A, Exp Date: 09/2026; Lot # 3010653A, Exp Date: 01/2027; Lot # 3010654A, 3010679A, 3010702A, Exp Date: 02/2027; Lot # 3010547A, Exp Date: 04/2026 b) NDC 0093-4068-10: Lot # 3010402A Exp Date: 02/2028; Lot # 3010593A, Exp Date: 07/2026, Lot # 3010610 Exp Date: 09/2026 **less...**

Classification:

Class II

Event Details

Event ID:

97755

Voluntary / Mandated:

Voluntary: Firm initiated

Product Type:

Drugs

Initial Firm Notification of Consignee or Public:

Letter

Status:

Ongoing

Distribution Pattern:

U.S. Nationwide

Recalling Firm:

Teva Pharmaceuticals USA, Inc
400 Interpace Pkwy Bldg A
Parsippany, NJ 07054-1120
United States

Press Release URL(s):

Press Release Not Issued For This Recall

Recall Initiation Date:

10/7/2025

Center Classification Date:

10/24/2025

Date Terminated:

N/A

***N/A -** *Not Available*

Update History

There is no history available for this product

Product Details

Product Description:

Prazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093 4069-01, b) 250 Capsules, NDC 0093-4069-52, c) 500 Capsules, NDC 0093-4069-05

Reason for Recall:

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Product Quantity:

107,673

Recall Number:

D-0106-2026

Code Information:

a) NDC 0093-4069-01: Lot # 3010403A, 3010385A, 3010404A, Exp Date: 02/2026; Lot # 3010405A, 3010510A, 3010528A, 3010354A, Exp Date: 03/2026; Lot # 3010592A, 3010605A, 3010611A, 3010612A, Exp Date: 08/2026; Lot # 3010655A, 3010703A, Exp Date: 02/2027 b) NDC 0093-4069-52: Lot # 3010430A, Exp Dat 11/2025, Lot # 3010613A, Exp Date: 08/2026 c) NDC 0093-4069-05: Lot # 3010406A, Exp Date: 02/2026 **less...**

Classification:

Class II

Event Details

Event ID:

97755

Voluntary / Mandated:

Voluntary: Firm initiated

Product Type:

Drugs

Initial Firm Notification of Consignee or Public:

Letter

Status:

Ongoing

Distribution Pattern:

U.S. Nationwide

Recalling Firm:

Teva Pharmaceuticals USA, Inc
400 Interpace Pkwy Bldg A
Parsippany, NJ 07054-1120
United States
Press Release URL(s):

Press Release Not Issued For This Recall

Recall Initiation Date:

10/7/2025

Center Classification Date:

10/24/2025

Date Terminated:

N/A

***N/A -** *Not Available*

Update History

There is no history available for this product